Ivosidenib and Ruxolitinib in Patients With Advanced Blood Cancers That Have IDH1 Gene MutationPhase MPNs
Condition(s):Myeloproliferative NeoplasmsLast Updated:March 6, 2024Not yet recruiting
Hide Studies Not Open or Pending
Condition(s):Myeloproliferative NeoplasmsLast Updated:March 6, 2024Not yet recruiting
Condition(s):Cerebral Palsy Spastic DiplegiaLast Updated:March 7, 2024Not yet recruiting
Condition(s):Beta-Thalassemia MajorLast Updated:March 6, 2024Not yet recruiting
Condition(s):Pharmacokinetics; Safety IssuesLast Updated:March 4, 2024Completed
Condition(s):Retinitis PigmentosaLast Updated:March 4, 2024Recruiting
Condition(s):Heart FailureLast Updated:March 4, 2024Not yet recruiting
Condition(s):Dementia; Alzheimer DiseaseLast Updated:March 22, 2024Not yet recruiting
Condition(s):Women’s Health: Neoplasm of BreastLast Updated:March 8, 2024Recruiting
Condition(s):Coronavirus Disease 2019; Severe Acute Respiratory Syndrome Coronavirus 2 InfectionLast Updated:March 6, 2024Completed
Condition(s):Post Acute Sequelae of SARS CoV 2 Infection; Obstructive Sleep ApneaLast Updated:March 4, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.